- Home
- AGIO vs HAPN Comparison
AGIO vs HAPN Comparison
Compare AGIO & HAPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | HAPN |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AGIO | HAPN |
|---|---|---|
| Price | $32.48 | $15.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $46.25 | $24.75 |
| AVG Volume (30 Days) | 686.1K | ★ 1.1M |
| Earning Date | 10-29-2026 | 10-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.78 |
| EPS | N/A | ★ 0.94 |
| Revenue | $43,011,000.00 | ★ $314,702,000.00 |
| Revenue This Year | $237.78 | N/A |
| Revenue Next Year | $92.30 | $19.08 |
| P/E Ratio | ★ N/A | $15.89 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.24 | $14.61 |
| 52 Week High | $46.00 | $21.25 |
Technical Indicators
Market Signals| Indicator | AGIO | HAPN |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 23.38 |
| Support Level | $32.17 | N/A |
| Resistance Level | $35.77 | $21.25 |
| Average True Range (ATR) | 1.18 | 0.45 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 51.25 | 9.39 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About HAPN Happen Inc. Common Stock
Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.